Colorectal News and Research

RSS

Cancer Research UK launches programme to turn genetic revolution into better treatment for cancer patients

Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.

13 Oct 2010

Patients with advanced cancer undergo common non-beneficial cancer screening tests

A sizeable proportion of patients with advanced cancer and a life expectancy of only a few years continue to undergo common cancer screening tests that are unlikely to provide meaningful benefit, according to a study in the October 13 issue of JAMA.

13 Oct 2010

Study demonstrates chitosan/IL-12 is an effective anti-tumor immunotherapy

A new study by a University of Arkansas biomedical engineer and his colleagues at the National Cancer Institute demonstrates further promise for chitosan/interleukin-12 as an effective anti-tumor immunotherapy.

13 Oct 2010

Imprime PGG and cetuximab increase overall response rate in metastatic colorectal cancer

A combination of Biothera's Imprime PGG and cetuximab (Erbitux) doubled the overall response rates for second- and third-line metastatic colorectal cancer patients participating in a Phase Ib/IIa clinical trial. The completed trial results were released yesterday at the 35th European Society for Medical Oncology (ESMO) Congress.

13 Oct 2010

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

QIAGEN and Abbott today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed.

From QIAGEN Manchester Limited 13 Oct 2010

Cancer patients getting unnecessary tests: Study

US researchers revealed that many cancer patients with only a few years to live often continue to get routine mammograms or blood tests for prostate cancer even though they are not likely to live long enough to benefit from them. This not only wastes money but also exposes patients to unnecessary worry and distress.

12 Oct 2010

Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors

Merck Serono, a division of Merck KGaA, Darmstadt, Germany has announced that new data presented today at the 35th Congress of the European Society for Medical Oncology (ESMO) have shown that patients with KRAS wild-type metastatic colorectal cancer (mCRC) who experienced early tumor shrinkage (within 8 weeks) during 1st line Erbitux (cetuximab) based treatment lived a median of 28.3 months.

12 Oct 2010

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.

11 Oct 2010

Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer

Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).

11 Oct 2010

Intestinal bacteria send signals that promote cell proliferation in Wnt signaling pathway

Microbes matter -- perhaps more than anyone realizes -- in basic biological development and, maybe, they could be a target for reducing cancer risks, according to University of Oregon researchers.

8 Oct 2010

Caris Target Now molecular tumor profiling increases PFS in cancer patients

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, today announced highlights from a multi-center, prospective, pilot study published in the Journal of Clinical Oncology.

7 Oct 2010

New microtechnology approach may prevent pelvic autonomic nerve injury in rectal cancer surgical procedure

Surgeons in Germany have found that using microtechnology to elec-tronically stimulate and monitor pelvic autonomic nerves may help prevent problems after a surgical procedure for rectal cancer, such as bladder, urinary and fecal incontinence, and sexual function disorders, according to a study reported at the 2010 Annual Clinical Congress of the American College of Surgeons.

7 Oct 2010

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 national research and training grants totaling $46,633,000 to 70 institutions nationwide in the first of two grants cycles for 2011.

7 Oct 2010

Cancer cells utilize energy-rich intermediates of sugar metabolism: Research

Cancer research is facing a radical change of direction. Cancer cells do not obtain their energy from the breakdown of sugar to carbon dioxide and water, but from energy-rich intermediates of sugar metabolism instead.

6 Oct 2010

AACR to host special conference on colorectal cancer

This October, the American Association for Cancer Research will host the special conference Colorectal Cancer: Biology to Therapy at the Loews Philadelphia Hotel. Hundreds of scientists, physicians and allied health professionals will gather and discuss new data on new screening methods and emerging therapies.

5 Oct 2010

Merck Serono to present Erbitux data at ESMO Congress

Merck Serono, a division of Merck KGaA, Darmstadt, Germany announces today that it will be presenting new data from several studies of Erbitux (cetuximab) in a range of solid tumor types including the first Phase II data in breast and prostate cancers. These data will be presented at the forthcoming 35th European Society for Medical Oncology Congress (ESMO) in Milan, October 8-12, 2010.

5 Oct 2010

Amgen announces PRIME '203' and '181' Phase 3 trial results

Amgen today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online in the Journal of Clinical Oncology.

5 Oct 2010

Study shows no difference between Bevacizumab and Ranibizumab efficacy in treating AMD

Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

4 Oct 2010

Socioeconomic status impacts colorectal cancer incidence

People living in economically deprived neighborhoods were more likely to be diagnosed with late-stage, non-localized colorectal cancer, even after researchers controlled for known colorectal cancer risk factors, according to data presented at the Third American Association for Cancer Research Conference on The Science of Cancer Health Disparities, being held Sept. 30-Oct. 3, 2010.

4 Oct 2010

Sulindac drug derivative effective in preventing colon cancer: Research

Researchers in the Division of Cancer Prevention, Department of Medicine, at Stony Brook University have discovered that a novel derivative of sulindac, a non-steroidal anti-inflammatory drug (NSAID) known to prevent colon cancer, is more effective and safer than sulindac in preventing colon cancer in animals. The study results are reported in the October issue of the journal Gastroenterology.

3 Oct 2010

Colorectal News and Research

Cancer Research UK launches programme to turn genetic revolution into better treatment for cancer patients

Patients with advanced cancer undergo common non-beneficial cancer screening tests

Study demonstrates chitosan/IL-12 is an effective anti-tumor immunotherapy

Imprime PGG and cetuximab increase overall response rate in metastatic colorectal cancer

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

Cancer patients getting unnecessary tests: Study

Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer

Intestinal bacteria send signals that promote cell proliferation in Wnt signaling pathway

Caris Target Now molecular tumor profiling increases PFS in cancer patients

New microtechnology approach may prevent pelvic autonomic nerve injury in rectal cancer surgical procedure

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

Cancer cells utilize energy-rich intermediates of sugar metabolism: Research

AACR to host special conference on colorectal cancer

Merck Serono to present Erbitux data at ESMO Congress

Amgen announces PRIME '203' and '181' Phase 3 trial results

Study shows no difference between Bevacizumab and Ranibizumab efficacy in treating AMD

Socioeconomic status impacts colorectal cancer incidence

Sulindac drug derivative effective in preventing colon cancer: Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News